Vaccine and Monoclonal Antibody That Enhance Mouse Resistance to Candidiasis

Adaptive Immunity to Fungi

“…This vaccination approach induces a robust antibody response in mice and confers protection during Pneumocystis pneumonia. Other fungal Ags that elicit a vigorous humoral response in experimental models have been reported (Devi 1996;Han et al 1999;Fleuridor et al 2001;Torosantucci et al 2005;Sandini et al 2011;Xin and Cutler 2011). Thus, immunoglobulin therapy represents a promising approach that could be used to treat mycoses in individuals with immunosuppression.…”

Immunization with Pneumocystis Cross-Reactive Antigen 1 (Pca1) Protects Mice against Pneumocystis Pneumonia and Generates Antibody to Pneumocystis jirovecii

“…The extent of protection that resulted from immunization with Pca1 was unexpected, since partial protection after immunization appears to be the typical outcome of immunization against fungal pathogens such as Candida, Aspergillus, and Cryptococcus (18)(19)(20)(21)(22). A number of potential vaccine candidates have been evaluated in animal models of PcP as well, but at best, they achieved only partial protection (15,(23)(24)(25)(26)(27).…”

Combining Proteomic Strategies and Molecular Display Technology for Development of Vaccines against Candida albicans

“…All control mice died within 25 d. In contrast, 100% and 80% of mice treated with subcutaneous and intranasal administration of Mdh1p, respectively, survived. These results indicated that, among the C. albicans antigens examined thus far, such as hyphal wall protein (Hwp1p), phosphoglycerate kinase (Pgk1p), and glyceraldehyde-3-phosphate dehydrogenase (Gap1p) [32], Mdh1p is currently the most effective antigen for use as a vaccine for C. albicans. Furthermore, an investigation of time-course variation in C. albicans under serum-containing conditions to identify virulencerelated molecules could also provide novel and effective antigenic proteins.…”